18 June 2020
Visiongain has launched a new pharma report Cardiac Rhythm Management Devices Market Report 2020-2030: Forecasts by Product (Pacemakers (Implantable & External), Cardiac Resynchronization Therapy (CRT-Defibrillator & CRT-Pacemakers), Defibrillators (Implantable Cardioverter Defibrillators (ICD) & External Defibrillator)), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global Cardiac Rhythm Management (CRM) Devices Market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that the market is projected to witness a healthy growth rate owing to the technological advancements coupled with the high adoption rate of cardiac rhythm management devices across the developed economies.
To access the data contained in this document please email firstname.lastname@example.org
Over recent years, heart irregularities have been the primary cause of death. According to estimates by the World Health Organization (WHO), around 17.9 million mortality occurs each year in cardiovascular diseases (CVDs). Because CVDs are slow to develop symptoms, it is usually known as the "silent epidemic." They are also considered to be one of the most costly conditions for treatment. CRM devices are not only used for the management and monitoring of heart problems but are also used for healing, repair, and healing. In America and Europe, the increase in aging populations is likely to cause an increase in the number of patients with heart rhythm disorders.
However, the therapeutic radiation used for cancer can influence an implantable patient's operation. Implantable equipment technology uses a CMOS, which is vulnerable to damage by therapeutic doses of radiation but can vary by type of equipment used. The fact that implants are highly susceptible and their malfunction can have serious consequences is one of the main factors limiting the extent to which cardiac rhythm management devices can be used. On the other hand, the high cost of these devices restricts the market growth.
North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing presence of CVDs patient pool in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the Cardiac Rhythm Management Devices Market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global cardiac rhythm management devices market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Cardiac Rhythm Management Devices Market.
The comprehensive market report features companies such as Abbott Laboratories, Asahi Kasei Corporation, AliveCor, BioTelemetry, Boston Scientific, Biotronik, BPL Medical Technologies, CardioComm Solutions, EPI Mobile Health Solutions, GE Healthcare, Hill-Rom Holdings, Koninklijke Philips, Lepu Medical Technology, Medtronic, Nihon Kohden, Shenzhen Mindray Bio-Medical Electronics, among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.
05 May 2021
Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.
29 April 2021
Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.
29 April 2021
Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.